Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH.

Oral Oncol. 2013 May;49(5):461-7. doi: 10.1016/j.oraloncology.2012.12.016. Epub 2013 Feb 4.

PMID:
23384718
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE.

Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.

PMID:
19201650
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).

Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, MacKay H.

Gynecol Oncol. 2013 Aug;130(2):269-74. doi: 10.1016/j.ygyno.2013.05.008. Epub 2013 May 11.

PMID:
23672928
[PubMed - indexed for MEDLINE]
4.

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.

BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368.

PMID:
20630061
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.

J Natl Cancer Inst. 2014 Aug 5;106(9). pii: dju215. doi: 10.1093/jnci/dju215. Print 2014 Sep.

PMID:
25099740
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.

Bhatt VR, Ganti AK.

Oral Oncol. 2013 Aug;49(8):e25. doi: 10.1016/j.oraloncology.2013.04.001. Epub 2013 Apr 28. No abstract available.

PMID:
23631847
[PubMed - indexed for MEDLINE]
7.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

PMID:
24470557
[PubMed - indexed for MEDLINE]
8.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators.

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
[PubMed - indexed for MEDLINE]
9.

Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).

Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G.

Anticancer Res. 2005 Nov-Dec;25(6C):4445-9.

PMID:
16334124
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

PMID:
22210086
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
[PubMed - indexed for MEDLINE]
12.

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE.

J Clin Oncol. 2003 May 15;21(10):1980-7.

PMID:
12743152
[PubMed - indexed for MEDLINE]
13.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

PMID:
23460714
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E; Princess Margaret Hospital Phase II Consortium; National Cancer Institute of Canada Clinical Trials Group Study.

J Clin Oncol. 2007 Jun 1;25(16):2178-83.

PMID:
17538162
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE.

Clin Cancer Res. 2012 Apr 15;18(8):2336-43. doi: 10.1158/1078-0432.CCR-11-2825. Epub 2012 Feb 27.

PMID:
22371453
[PubMed - indexed for MEDLINE]
Free Article
16.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

PMID:
23405260
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D.

J Natl Cancer Inst. 2005 Jun 15;97(12):880-7.

PMID:
15956649
[PubMed - indexed for MEDLINE]
Free Article
18.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.

J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12.

PMID:
22412142
[PubMed - indexed for MEDLINE]
Free Article
19.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL.

J Clin Oncol. 2004 Jan 1;22(1):77-85.

PMID:
14701768
[PubMed - indexed for MEDLINE]
Free Article
20.

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.

Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE.

Mol Oncol. 2013 Jun;7(3):359-68. doi: 10.1016/j.molonc.2012.11.001. Epub 2012 Nov 14.

PMID:
23200321
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk